Unity Biotechnology Inc (NASDAQ:UBX)’s stock price shot up 13.6% on Friday . The stock traded as high as $9.50 and last traded at $9.50. 1,292,863 shares changed hands during mid-day trading, an increase of 507% from the average session volume of 212,825 shares. The stock had previously closed at $8.36.
A number of research firms have commented on UBX. Zacks Investment Research raised shares of Unity Biotechnology from a “sell” rating to a “hold” rating and set a $10.00 price objective for the company in a research report on Tuesday, May 14th. Mizuho reaffirmed a “buy” rating on shares of Unity Biotechnology in a research report on Wednesday, March 6th. Finally, Cantor Fitzgerald began coverage on shares of Unity Biotechnology in a research report on Wednesday, March 6th. They set an “overweight” rating and a $21.00 price objective for the company. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $22.00.
The business has a 50-day simple moving average of $8.69.
Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA lifted its holdings in shares of Unity Biotechnology by 5,850.0% during the first quarter. BNP Paribas Arbitrage SA now owns 5,355 shares of the company’s stock worth $43,000 after buying an additional 5,265 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Unity Biotechnology by 416.4% during the fourth quarter. Legal & General Group Plc now owns 3,863 shares of the company’s stock worth $63,000 after buying an additional 3,115 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Unity Biotechnology during the first quarter worth $105,000. Citigroup Inc. lifted its holdings in shares of Unity Biotechnology by 374.7% during the fourth quarter. Citigroup Inc. now owns 6,589 shares of the company’s stock worth $107,000 after buying an additional 5,201 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY acquired a new stake in shares of Unity Biotechnology during the fourth quarter worth $144,000. 38.21% of the stock is owned by institutional investors.
Unity Biotechnology Company Profile (NASDAQ:UBX)
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.
Featured Story: Diversification For Individual Investors
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.